Scientists at Japan-based Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) and colleague...
Alzheimer’s Disease (AD), the most common type of dementia, causes the death of neurons and leads to shrinking of ...
In an email interaction with BioSpectrum, EpimAb’s Founder and CEO, Dr Chengbin Wu tells us more about the company...
Pharmacologists at the University of Sydney in Australia have found tantalising clues as to why low-dose CBD products co...
Inhalon Biopharma, Inc., a US-based clinical-stage immunotherapy company developing an inhaled "muco-trapping" anti...
Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solution...
Dr Stephen Inns and his team from the University of Otago, in New Zealand (NZ) have secured almost $250,000 from the Hea...
After years of research, the field of gene therapies is at a tipping point. Recent years have seen immense progress in t...
Terumo Europe and University Medical Center Utrecht (UMC Utrecht) have announced that they signed a Memorandum of Unders...
According to a recent study done by researchers in Taiwan, angiotensin receptor blockers (ARBs) may have protective effe...
Millennials Have Elevated Risks for Some Obesity-Related Cancers The American Cancer Society led a study that l...
University of Otago scientists in New Zealand (NZ) have opened the door to improved treatment of brain dysfunction which...
A research team and collaborators at the Korea Advanced Institute of Science and Technology has revealed a new...
Australia-based Agilex Biolabs has launched its new $1.5M vaccine and immuno-biology laboratory. The facility, the most ...
Researchers at Keio University, Japan, describe cutting edge mass spectrometry technology that offers unpreced...
Scientists at Australia's Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Peter MacCallu...
Israeli university- Ben-Gurion University of Negev (BGU) scientists have found that a gene activated in glioblastoma, a ...
Paris-based Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, ...
